REPL Replimune Group |
$11.20
+107.0% |
August 2, 2026
|
RP1 (vusolimogene oderparepvec)
In Advanced Melanoma
|
BLA
|
6/26/2026 - Provided Update
Replimune Group, Inc. announced that The FDA considers this a complete, class 1 response with a goa…
Full Summary
|
LNTH Lantheus |
$99.64
-1.3% |
August 13, 2026
|
MK-6240
PET Imaging Agent Targeting Tau in Alzheimer's Disease
|
NDA
|
10/28/2025 - PDUFA Date
Lantheus Holdings, Inc. announced that The FDA has set a Prescription Drug User Fee Act (PDUFA) tar…
Full Summary
|
MRK Merck & Co., Inc. |
$130.49
+0.5% |
August 17, 2026
|
KEYTRUDA QLEX™
Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
|
supplemental New Drug Application (sNDA) Priority Review
|
4/20/2026 - PDUFA Date
Merck announced that The FDA set a Prescription Drug User Fee Act (PDUFA), or target action, date o…
Full Summary
|
SVRA Savara |
$5.46
-1.4% |
August 22, 2026
|
MOLBREEVI
Treatment for aPAP.
|
BLA
|
2/20/2026 - PDUFA Date
Savara Inc announced that The FDA granted Priority Review with a PDUFA action date of August 22, 202…
Full Summary
|
JAZZ Jazz Pharmaceuticals |
$252.86
-2.1% |
August 25, 2026
|
Ziihera
For the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
|
supplemental New Drug Application (sNDA)
|
4/27/2026 - PDUFA Date
Jazz Pharmaceuticals plc announced that The FDA has set a PDUFA target action date of August 25, 20…
Full Summary
|
GILD Gilead Sciences |
$130.21
-0.8% |
August 27, 2026
|
BIC/LEN
treatment of HIV
|
NDA
|
4/29/2026 - PDUFA Date
Gilead Sciences, Inc announced that The FDA has granted priority review of the application and assi…
Full Summary
|
NUVL Nuvalent |
$123.96
|
September 18, 2026
|
zidesamtinib
ALK-selective inhibitor, neladalkib, and novel ROS1-selective inhibitor, zidesamtinib
|
NDA
|
11/19/2025 - PDUFA Date
Nuvalent, Inc. announced that FDA assigns PDUFA target action date of September 18, 2026
Full Summary
|
RARE Ultragenyx Pharmaceutical |
$24.91
-4.3% |
September 19, 2026
|
UX111
For Sanfilippo syndrome type A (MPS IIIA)
|
BLA
|
4/2/2026 - PDUFA Date
Ultragenyx Pharmaceutical announced that The FDA set a Prescription Drug User Fee Act (PDUFA) action…
Full Summary
|
IONS Ionis Pharmaceuticals |
$51.77
-2.8% |
September 22, 2026
|
Zilganersen
for the treatment of children and adults Alexander disease (AxD).
|
NDA Priority Review
|
3/23/2026 - PDUFA Date
Ionis Pharmaceuticals, Inc announced that The FDA has set a Prescription Drug User Fee Act (PDUFA) …
Full Summary
|
ALMS Alumis |
$28.25
-2.4% |
Q3 2026
|
ESK-001
In Moderate-to-Severe Plaque Psoriasis
|
|
7/24/2025 - Topline Readout
Alumis Inc. announced that Topline Readout Expected in Q3 2026
Full Summary
|
SLN Silence Therapeutics |
$10.49
-9.7% |
Q3 2026
|
divesiran
In patients with polycythemia vera
|
Phase 2
|
10/23/2025 - Top-line results
Silence Therapeutics plc announced that Initial topline results from the SANRECO Phase 2 study are …
Full Summary
|
ROIV Roivant Sciences |
$33.91
-1.8% |
Q3 2026
|
Brepocitinib
Systemic Lupus Erythematosus
|
NDA
|
3/3/2026 - PDUFA Date
Priovant Therapeutics announced that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) …
Full Summary
|
IMMX Immix Biopharma |
$8.32
-2.7% |
Q3 2026
|
NXC-201
NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.
|
|
3/30/2026 - Top-line results
Immix Biopharma, Inc. announced that NEXICART-2 enrollment is complete, meeting Company guidance, w…
Full Summary
|
QURE uniQure |
$43.63
+3.4% |
Q3 2026
|
AMT-130
Huntington's Disease
|
|
4/30/2026 - Provided Update
uniQure N.V. announced the Company held a Pre-Submission Meeting with the United Kingdom's (UK) Med…
Full Summary
|
ALLR Allarity Therapeutics |
$1.21
-1.6% |
Q3 2026
|
Stenoparib
For ovarian cancer (AOC)
|
|
5/5/2026 - Provided Update
Allarity Therapeutics, Inc. announced that its active pharmaceutical ingredient (API) manufacturing …
Full Summary
|
STOK Stoke Therapeutics |
$28.86
-3.9% |
Q3 2026
|
zorevunersen
For the treatment of Dravet syndrome with a confirmed mutation,
|
Phase 3
|
6/30/2026 - Data readout
Stoke Therapeutics, Inc announced that Phase 3 data readout is anticipated in the third quarter of …
Full Summary
|
MRK Merck & Co., Inc. |
$130.49
+0.5% |
October 10, 2026
|
I-DXd
In patients with pretreated extensive-stage small cell lung cancer (ES-SCLC).
|
BLA
|
4/13/2026 - PDUFA Date
Daiichi Sankyo and Merck announced that The Prescription Drug User Fee Act (PDUFA) date, the FDA …
Full Summary
|
SVRA Savara |
$5.46
-1.4% |
November 22, 2026
|
Molgramostim (IMPALA-2)
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
4/15/2026 - PDUFA Date
Savara Inc. announced Prescription Drug User Fee Act (PDUFA) Target Action Date Extended by Three Mo…
Full Summary
|
BBIO BridgeBio Pharma |
$80.09
-2.5% |
November 27, 2026
|
BBP-418
Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
|
|
5/27/2026 - PDUFA Date
BridgeBio Announces that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target actio…
Full Summary
|
COGT Cogent Biosciences |
$38.93
-5.9% |
November 30, 2026
|
bezuclastinib
In patients with non-advanced systemic mastocytosis
|
NDA
|
5/28/2026 - PDUFA Date
Cogent Biosciences, Inc announced The FDA has granted the application Priority Review and assigned …
Full Summary
|
COGT Cogent Biosciences |
$38.93
-5.9% |
December 30, 2026
|
bezuclastinib
In patients with non-advanced systemic mastocytosis
|
NDA
|
3/16/2026 - PDUFA Date
Cogent Biosciences, Inc announced that the Prescription Drug User Fee Act (PDUFA) target action date…
Full Summary
|
ANNX Annexon |
$5.09
-3.4% |
H2 2026
|
ANX007
Geographic Atrophy
|
|
9/9/2024 - Data
Annexon, Inc. announced that ARCHER II Phase 3 Pivotal Program in GA Underway with Data Expected Se…
Full Summary
|
ANNX Annexon |
$5.09
-3.4% |
H2 2026
|
ANX007
Geographic Atrophy
|
Phase 3
|
12/5/2024 - Provided Update
Annexon, Inc. Pivotal Phase 3 ARCHER II in GA Actively Enrolling with Data Expected Second Half 2026
Full Summary
|
KNSA Kiniksa Pharmaceuticals International |
$74.34
-4.9% |
H2 2026
|
KPL-387
In recurrent pericarditis
|
Phase 2
|
6/5/2025 - Data
Kiniksa Pharmaceuticals International announced that Phase 2 data expected in 2H 2026
Full Summary
|
RNA Avidity Biosciences |
$11.35
-1.0% |
H2 2026
|
Delpacibart Braxlosiran
In People Living with Facioscapulohumeral Muscular Dystrophy
|
BLA
|
6/9/2025 - BLA Filing
Avidity Biosciences, Inc. announced that Planning accelerated approval BLA submission in H2 2026
Full Summary
|
RGNX REGENXBIO |
$9.69
-4.2% |
Q4 2026
|
surabgene lomparvovec
for Wet AMD
|
|
10/6/2025 - Top-line data
REGENXBIO Inc. announced that Topline pivotal data expected in Q4 2026
Full Summary
|
ACET Adicet Bio |
$9.11
+0.6% |
H2 2026
|
ADI-001
B cell non-Hodgkin's lymphoma (NHL)
|
Phase 1
|
10/16/2025 - Preclinical Data
Adicet Bio, Inc. announced that Preliminary clinical data from the Phase 1 trial expected in 2H/2026
Full Summary
|
VRCA Verrica Pharmaceuticals |
$5.22
-0.8% |
Q4 2026
|
YCANTH™ (cantharidin)
For molluscum contagiosum, which is primarily a pediatric disease.
|
|
10/20/2025 - Provided Update
Verrica is initiating activities to support this regulatory submission, which could be filed as earl…
Full Summary
|
MIRM Mirum Pharmaceuticals |
$105.95
-5.9% |
Q4 2026
|
Maralixibat
Alagille Syndrome
|
|
3/16/2026 - Top-line data
Mirum Pharmaceuticals, Inc. announced that the Topline data expected in Q4 2026
Full Summary
|
ACRS Aclaris Therapeutics |
$5.20
-2.3% |
Q4 2026
|
ATI-045
In Atopic Dermatitis (AD)
|
|
3/18/2026 - Top-line results
Aclaris Therapeutics, Inc. announced that the Top line results are expected in the fourth quarter o…
Full Summary
|
ENTA Enanta Pharmaceuticals |
$12.60
-3.1% |
Q4 2026
|
EDP-978
Treatment of Urticaria
|
|
4/13/2026 - Top-line data
Enanta Pharmaceuticals, Inc announced that the Topline Data Expected in Q4 2026
Full Summary
|
BBIO BridgeBio Pharma |
$80.09
-2.5% |
H2 2026
|
BBO-11818
Potent panKRAS Inhibitor
|
|
4/20/2026 - Clinical Data
BridgeBio Oncology Therapeutics, Inc. announced that the Updated Phase 1 clinical data are expected …
Full Summary
|
ADCT ADC Therapeutics |
$1.05
-5.4% |
Q4 2026
|
ZYNLONTA
In patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
|
|
6/30/2026 - Data
ADC Therapeutics SA announced that the Full data expected in fourth quarter of 2026
Full Summary
|
PFE Pfizer |
$25.10
+0.8% |
Q4 2026
|
TALZENNA
Oral inhibitor of poly ADP-ribose polymerase
|
supplemental New Drug Application (sNDA) Priority Review
|
7/22/2026 - PDUFA Date
Pfizer Inc announced that the FDA has set a Prescription Drug User Fee Act (PDUFA) action date in …
Full Summary
|
NAMS NewAmsterdam Pharma |
$27.79
-2.4% |
H2 2026
|
Obicetrapib
CETP inhibitor
|
|
7/24/2026 - Provided Update
NewAmsterdam Pharma Company N.V announced that the European Commission decision expected in 2H26
Full Summary
|
NUVB Nuvation Bio |
$6.33
-5.6% |
January 4, 2027
|
IBTROZI
In Advanced ROS1-Positive Non-Small Cell Lung Cancer
|
supplemental New Drug Application (sNDA)
|
5/6/2026 - PDUFA Date
Nuvation Bio Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted a sup…
Full Summary
|
CGEM Cullinan Therapeutics |
$16.50
-5.8% |
February 27, 2027
|
zipalertinib
For patients with heavily pre-treated EGFR ex20ins mutation NSCLC
|
NDA
|
4/28/2026 - PDUFA Date
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, announced that The…
Full Summary
|
BMRN BioMarin Pharmaceutical |
$60.02
-0.9% |
February 28, 2027
|
vosoritide
Children with achondroplasia
|
supplemental New Drug Application (sNDA)
|
7/13/2026 - PDUFA Date
BioMarin Pharmaceutical Inc. announced that The FDA has set a Prescription Drug User Fee Act (PDUFA…
Full Summary
|
PMVP PMV Pharmaceuticals |
$1.11
-1.8% |
Q1 2027
|
rezatapopt
in patients with advanced solid tumors
|
NDA
|
10/24/2025 - NDA Filing
PMV Pharmaceuticals, announced that
Full Summary
|
STOK Stoke Therapeutics |
$28.86
-3.9% |
Q1 2027
|
zorevunersen
For the treatment of Dravet syndrome with a confirmed mutation,
|
|
6/30/2026 - rolling submission
Stoke Therapeutics, Inc to initiate a rolling New Drug Application (NDA) submission to the U.S. Food…
Full Summary
|
ABEO Abeona Therapeutics |
$6.42
-0.8% |
Q1 2027
|
PMN310
PMN310 is a novel monoclonal antibody
|
|
7/28/2026 - Top-line results
ProMIS Neurosciences Inc. announced that 12-month topline results expected in Q1 2027
Full Summary
|
PHVS Pharvaris |
$32.62
-3.7% |
April 23, 2027
|
Deucrictibant
For bradykinin-B2-receptor
|
|
7/6/2026 - PDUFA Date
Pharvaris announced that The FDA has set a Prescription Drug User Fee Act (PDUFA) target action dat…
Full Summary
|
ORGO Organogenesis |
$2.37
-3.3% |
April 27, 2027
|
ReNu
for Knee Osteoarthritis
|
|
7/6/2026 - PDUFA Date
Organogenesis Holdings Inc. announced that the FDA has set a Prescription Drug User Fee Act (PDUFA) …
Full Summary
|
AXSM Axsome Therapeutics |
$217.99
-7.1% |
May 1, 2027
|
AXS-12
Narcolepsy
|
|
7/15/2026 - PDUFA Date
Axsome Therapeutics, Inc. announced that the FDA sets PDUFA target action date of May 1, 2027
Full Summary
|
BBIO BridgeBio Pharma |
$80.09
-2.5% |
May 8, 2027
|
Encaleret
Autosomal Dominant Hypocalcemia Type 1 (ADH1)
|
NDA
|
7/22/2026 - PDUFA Date
BridgeBio Pharma, Inc. announced that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) …
Full Summary
|
BMY Bristol Myers Squibb |
$65.44
+0.9% |
May 13, 2027
|
MeziKd
Relapsed or Refractory Multiple Myeloma
|
NDA
|
7/13/2026 - PDUFA Date
Bristol Myers Squibb announced that The U.S. FDA has assigned a target action date of May 13, 2027
Full Summary
|
NBTX Nanobiotix |
$38.38
-4.4% |
H1 2027
|
NANORAY-312
head and neck squamous cell cancers.
|
|
10/24/2025 - Interim Data
Nanobiotix estimates that NANORAY-312 interim data will be analyzed and reported, after both the req…
Full Summary
|
LBRX LB Pharmaceuticals |
$40.08
-2.0% |
H2 2027
|
LB-102
In Patients With Bipolar Depression
|
|
3/25/2026 - Top-line data
LB Pharmaceuticals Inc announced that the Topline data expected in 2H 2027
Full Summary
|
AURA Aura Biosciences |
$7.01
-1.4% |
H2 2027
|
Belzupacap Sarotalocan (AU-011)
Non-Muscle Invasive Bladder Cancer (NMIBC)
|
|
6/1/2026 - Top-line data
Aura Biosciences Announced that the Topline data for the 15-month primary endpoint are anticipated…
Full Summary
|
IONS Ionis Pharmaceuticals |
$51.77
-2.8% |
H2 2027
|
ION582
Angelman syndrome
|
|
7/6/2026 - Top-line data
Ionis Pharmaceuticals, Inc announced Topline data from REVEAL anticipated in 2H 2027 -
Full Summary
|
EYPT Eyepoint Pharmaceuticals |
$12.25
-4.7% |
Q4 2027
|
DURAVYU
In patients with non-proliferative diabetic retinopathy (NPDR).
|
|
7/30/2026 - Top-line data
EyePoint, Inc. announced that Topline data for both DME trials are anticipated in the fourth quart…
Full Summary
|
